A pilot clinical trial to assess feasibility, facilitators and barriers of continuous glucose monitoring in Asian Americans with type 2 diabetes
一项试点临床试验,旨在评估患有 2 型糖尿病的亚裔美国人进行连续血糖监测的可行性、促进因素和障碍
基本信息
- 批准号:10511276
- 负责人:
- 金额:$ 25.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-23 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAdvocacyAffectAgeAsianAsian AmericansBody mass indexCOVID-19 pandemicCOVID-19 severityCardiovascular DiseasesCaringChinaChineseChinese AmericanClinical TrialsCommunitiesComplications of Diabetes MellitusDataDiabetes MellitusDiagnosisEast AsianEducationEnvironmentEthnic groupExclusionFaceFutureGenerationsGuidelinesHealthHealth TechnologyHealthcareImmigrantImpaired cognitionInterventionJapaneseKidney DiseasesKoreansLanguageLimited English ProficiencyLinkLipidsMeasuresMedicaidMedicareMetabolicMethodsMinorityModelingNational Health and Nutrition Examination SurveyNeuropathyNon-Insulin-Dependent Diabetes MellitusNot Hispanic or LatinoOutcomeParticipantPatientsPopulationPrevalencePreventionProtocols documentationProviderQuality of lifeRaceRandomized Clinical TrialsRandomized Controlled TrialsReportingResourcesRetinal DiseasesSARS-CoV-2 infectionSiteSouth AsianSubgroupTechnologyUninsuredVariantarmcompliance behaviorcostdesigndiabetes riskdigitalethnic minorityglucose monitorglycemic controlhealth care disparityimplementation evaluationimplementation processimplementation strategyinnovationliteracymonitoring deviceopen labelpandemic diseasepolicy implicationprogramsracial and ethnic disparitiessecondary outcomesexskillssocial health determinantssocial stigmasoutheast Asiantoolvocalization
项目摘要
Project Summary/Abstract
Rates of Type 2 Diabetes (T2D) are increasing both nationally and globally. In addition to known T2D
complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease, T2D is known to
affect cognitive impairment and even severity of COVID-19 infection. A few studies have shown the benefit of
Continuous Glucose Monitoring (CGM) devices for better glycemic management in T2D populations. While
prevention and management protocols for T2D are ubiquitous, there continue to exist large racial/ethnic
disparities amongst the general US population. Asian Americans (AA), specifically Chinese-Americans, present
with much higher T2D prevalence and face disparities in T2D care for the following reasons: 1) Stigma arising
from the “model minority myth”, exacerbated by the rise in anti-Asian sentiments during the COVID-19
pandemic; 2) Higher T2D unawareness rate; 3) Cultural and language barriers including limited digital literacy
and English proficiency; and 4) Historical exclusion from T2D studies, including those on CGM devices and
T2D, in which culturally-relevant facilitators and barriers to CGM use have yet to be evaluated in AAs. This
study will specifically examine how T2D could be better managed in Chinese Americans through a CGM
intervention, as compared to standard fingerstick glucose monitoring (FSGM). We will be conducting a 6-
month, single-site, open-labeled randomized controlled trial examining CGM versus no CGM (FSGM) use in
1st-generation Chinese Americans. Our specific aims are: Sp. Aim 1: In a pilot 6-month randomized clinical
trial, we will examine the impact of CGM use vs. No CGM among 1st generation Chinese Americans with T2D.
Sub-Aim 1.1. Evaluate feasibility (adherence and consistency) and quality of life measures during CGM use in
this population. Sub-Aim 1.2. Generate precision estimates of the distribution of the secondary outcomes (6-
month glycemic control and lipid markers) in both arms to inform a future randomized clinical trial (RCT). Sp.
Aim 2: Identify multi-level barriers and facilitators of CGM use for Chinese Americans with T2D, using a
socioecological framework (patient-level, provider-level, and community/environment level). We will evaluate
the implementation process (facilitators and impediments), resource requirements, and intermediate patient
adherence outcomes for the program using mixed-methods approaches. These will inform design of culturally-
tailored intervention for a larger randomized controlled trial.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE L KING其他文献
GEORGE L KING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE L KING', 18)}}的其他基金
A pilot clinical trial to assess feasibility, facilitators and barriers of continuous glucose monitoring in Asian Americans with type 2 diabetes
一项试点临床试验,旨在评估患有 2 型糖尿病的亚裔美国人进行连续血糖监测的可行性、促进因素和障碍
- 批准号:
10709518 - 财政年份:2022
- 资助金额:
$ 25.56万 - 项目类别:
Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes
长期 1 型糖尿病患者心血管疾病 (CVD) 的特征
- 批准号:
10543994 - 财政年份:2021
- 资助金额:
$ 25.56万 - 项目类别:
Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes
长期 1 型糖尿病患者心血管疾病 (CVD) 的特征
- 批准号:
10372462 - 财政年份:2021
- 资助金额:
$ 25.56万 - 项目类别:
Pyruvate kinase M2 levels and activation as protective factors for diabetic nephropathy
丙酮酸激酶 M2 水平和激活作为糖尿病肾病的保护因素
- 批准号:
9235747 - 财政年份:2016
- 资助金额:
$ 25.56万 - 项目类别:
Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration
类视黄醇结合蛋白 3 (RBP3) 的表征:在患有极度糖尿病病程的人群中发现的针对糖尿病视网膜病变的保护因子
- 批准号:
10320034 - 财政年份:2016
- 资助金额:
$ 25.56万 - 项目类别:
Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration
类视黄醇结合蛋白 3 (RBP3) 的表征:在患有极度糖尿病病程的人群中发现的针对糖尿病视网膜病变的保护因子
- 批准号:
10543746 - 财政年份:2016
- 资助金额:
$ 25.56万 - 项目类别:
Identification of Retinoid-Binding Protein 3 (RBP3): A Protective Factor against Diabetic Retinopathy Using Retina from People with Extreme Duration of Diabetes
类维生素A结合蛋白3 (RBP3)的鉴定:利用糖尿病病程极长的人的视网膜来鉴定糖尿病视网膜病变的保护因子
- 批准号:
9006846 - 财政年份:2016
- 资助金额:
$ 25.56万 - 项目类别:
Validation of Potential Protective Factors from Diabetic Complications
验证糖尿病并发症的潜在保护因素
- 批准号:
8922182 - 财政年份:2011
- 资助金额:
$ 25.56万 - 项目类别:
Validation of Potential Protective Factors from Diabetic Complications
验证糖尿病并发症的潜在保护因素
- 批准号:
8241364 - 财政年份:2011
- 资助金额:
$ 25.56万 - 项目类别:
Protective Factors Against the Development of Microvascular Complications
防止微血管并发症发生的保护因素
- 批准号:
8150968 - 财政年份:2010
- 资助金额:
$ 25.56万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 25.56万 - 项目类别:
Fellowship Programs